<DOC>
	<DOCNO>NCT03074825</DOCNO>
	<brief_summary>Chiauranib may stop growth tumor cell block Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R target . This clinical trial study efficacy safety chiauranib work treat patient relapsed refractory non-Hodgkin 's lymphoma , meantime , explore latent biomarkers accompany chiauranib , well relevancy clinical benefit .</brief_summary>
	<brief_title>Study Chiauranib Relapsed/Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>1 . Male Female , age ≥ 18 yr ≤70 yr ; 2 . Histological cytological confirmation nonHodgkin 's lymphoma（NHL） , include diffuse large Bcell lymphoma , peripheral Tcell lymphoma aggressive NHLs determine investigator . 3 . Patients NHL refractory least 2 different chemotherapy , standard therapy exist ; 4 . At least 1 lesion accurately measure , define Lugano 2014 criterion . 5 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 ; 6 . Subjects receive anticancer therapy ( include chemotherapy , radiotherapy , immunotherapy surgical therapy , et al ) beyond 4 week prior study entry ; Subjects receive mitomycin chemotherapy beyond 6 week prior study entry ; Subjects receive autologous stem cell transplantation beyond 3 month prior study entry ; 7 . Laboratory criteria follow : Complete blood count : hemoglobin ( Hb ) ≥90g/L ; absolute neutrophil count ( ANC ) ≥1.5×109/L ; platelet &gt; =90×109/L Biochemistry test : total bilirubin≦1.5×ULN ; alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) ≦1.5×ULN ; ( ALT , AST≦5×ULN liver involve ) ; serum creatinine ( cr ) ≦1.5×ULN ; Coagulation test : International Normalized Ratio ( INR ) &lt; 1.5 8 . Life expectancy least 12 week . 9 . Willingness sign write informed consent document . 1 . Patients prior invasive malignancy exception curativelytreated basal cell squamous cell carcinoma skin cervical carcinoma situ , unless receive curative treatment document evidence recurrence past five year ; 2 . Clinical evidence central nervous system involvement ; 3 . Have uncontrolled significant cardiovascular disease , include : 1 . Congestive heart failure , unstable angina pectoris , myocardial infarction within 6 month prior study entry ; arrhythmia , Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % require treatment agent screen stage . 2. primary cardiomyopathy ( dilate cardiomyopathy , hypertrophic cardiomyocyte , arrhythmogenic right ventricular cardiomyopathy , restrictive cardiomyopathy , et , al ) 3 . History significant QT interval prolongation , Corrected QT Interval ( QTc ) &gt; 450 m prior study entry 4 . Symptomatic coronary heart disease require treatment agent 5 . Uncontrolled hypertension ( &gt; 140/90 mmHg ) single agent ; 4 . Have active bleeding current thrombotic disease , patient bleed potential , receive anticoagulation therapy ; within 2 month prior screen ; 5 . Proteinuria positive ( ≥1g/24h ) ; 6 . History deep vein thrombosis pulmonary embolism ; 7 . Have unsolved toxicity ( &gt; grade 1 ) prior anticancer therapy ; 8 . Have clinical significant gastrointestinal abnormality , e.g. , unable swallow , chronic diarrhea , ileus , would impair ingestion , transportation absorption oral agent , patient undergone gastrectomy ; 9 . History organ transplantation Allogeneic bone marrow transplantation ; 10 . Major surgery within 6 week minor surgery within 2 week prior screen ( exclude placement vascular access biopsy ) involve general anaesthesia respiratory assistance ; 11 . Serologically positive HIV , hepatitis B C , serious infectious disease ; 12 . History interstitial lung disease ( ILD ) ; 13 . Previous treatment aurora kinase inhibitor ; 14 . Patients appropriate ready autologous stem cell transplantation ; 15 . Any mental cognitive disorder , would impair ability understand inform consent document operation compliance study ; 16 . Candidate drug alcohol abuse ; 17 . Participants reproductive potential willing use adequate contraceptive measure duration study ( male female participant ) .Pregnant breastfeed woman . Female participant must negative urinary serum pregnancy test do evidence postmenopausal status ( Defined absence menstruation great 12 month , bilateral oophorectomy hysterectomy ) ; 18 . Any condition inappropriate study opinion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>Relapsed/Refractory</keyword>
	<keyword>Aurora kinase B</keyword>
</DOC>